NCT01317901 - A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

April 30, 2013

Study Completion Date

June 30, 2013

Conditions

B-cell Small Lymphocytic Lymphoma Recurrent

Interventions

DRUG

TRU-016

100 mg TRU-016 lyophilized solution for infusion at 10 or 20 mg/kg (or 6 mg/kg, if necessary) on Days 1 and 15 of each 28 day cycle

DRUG

Bendamustine

Bendamustine by IV administration on Days 1 and 2 of each 28 day cycle.

DRUG

Rituximab

Rituximab by IV administration at 375 mg/m\^2 on Day 2 of each 28 day cycle.

Trial Locations (6)

Site Reference ID/Investigator# 61542, Augusta

Site Reference ID/Investigator# 61543, Birmingham

Site Reference ID/Investigator# 61523, Omaha

Site Reference ID/Investigator# 61522, Hackensack

Site Reference ID/Investigator# 61544, Chapel Hill

Site Reference ID/Investigator# 61524, Seattle